“Now more than ever, real-world evidence solutions are transforming healthcare. With the addition of NoviSci’s novel analytics platform and experienced team, Target provides a highly adaptive environment to accelerate insights and reproducible research output from real-world data to various stakeholders in the healthcare ecosystem, including our pharmaceutical industry partners, healthcare investigator partners, government agencies and payor organizations.” ![]() Neal Bibeau, Chief Executive Officer of Target RWE, said, “Target RWE’s proven real-world data and evidence solutions continue to grow in breadth, depth and value for our research and industry partners. Financial terms of the transactions were not disclosed. This expanded partnership further validates the importance of real-world data on a global scale and the differentiated capabilities and solutions that Target RWE and NoviSci offer together. Related to this acquisition, Amgen Inc., a strategic investor in and collaborator with NoviSci, has also made a strategic investment in the combined company to fuel growth, joining existing Target RWE investors Norwest Venture Partners and 22C Capital. The acquisition significantly broadens Target RWE’s data analytics capabilities and will enable the company to meet increasing demand for high quality evidence from real-world data. The market maker for Net Avenue Technologies IPO is Shreni Shares.DURHAM, N.C.-( BUSINESS WIRE)-Target RWE, a leading real-world evidence (RWE) solutions company for the pharmaceutical and biotech industries based in Durham, North Carolina, today announced the acquisition of NoviSci, Inc., a software analytics and services company whose innovative technologies enable the visualization and analysis of health data using modern epidemiological methods and sound scientific principles. Shreni Shares Limited is the book-running lead manager of the Net Avenue Technologies IPO, while Bigshare Services Pvt Ltd is the registrar for the issue. The proceeds from the issue will be utilised towards customer acquisition, marketing and awareness, funding working capital requirements, general corporate purpose, and issue expenses. ![]() The minimum lot size investment for HNI was 2 lots (16,000 shares) amounting to Rs 2,88,000. The minimum amount of investment required by retail investors was Rs 1,44,000. The company fixed the price band at Rs 16-18 per equity share for the IPO.įor investors, the minimum lot size to apply for the IPO was 8,000 shares. The IPO comprised a fresh issue of 37,92,000 equity shares for public subscription with a face value of Rs 1 each. ![]() The Net Avenue Technologies IPO is likely to be listed on NSE SME on December 7, while the share allotment is likely to take place on December 5. ‘Grey market premium’ indicates investors’ readiness to pay more than the issue price. The GMP is based on market sentiments and keeps changing. The Rs 11 grey market premium or GMP means the grey market is expecting a 61.11 per cent listing gain from the public issue. The price band of the Rs 10.25-crore Net Avenue Technologies SME IPO was fixed at Rs 16-18 a share.Īccording to market observers, unlisted shares of Net Avenue Technologies were trading Rs 11 higher in the grey market as compared with its issue price. ![]() The portion for qualified institutional buyers (QIBs) was subscribed 61.99 times. The category meant for non-institutional investors received an overwhelming 616.24 times subscription, while the quota for retail individual investors (RIIs) got subscribed a whopping 721.68 times. As per data available till 6:00 pm on the final day of bidding on Monday, the 10.25-crore IPO got a whopping 511 times subscription, receiving bids for 1,93,81,04,000 shares as against 37,92,000 shares on offer. The SME IPO has got a blockbuster response from investors. Net Avenue Technologies IPO Closes: The initial public offering (IPO) of Net Avenue Technologies, which opened for public subscription on November 30, has closed on Monday, December 4.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |